Clinical Trial Update: Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS [Phase 2]

View source ↗

Summary

This ClinicalTrials.gov update reports results from a Phase 2 open-label controlled trial of eculizumab in adolescents with plasma-therapy-resistant atypical he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome

Drugs mentioned

• SOLIRIS (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Atypical Hemolytic Uremic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2014-12-03